Skip to main content
. 2022 Jun 15;132(12):e154941. doi: 10.1172/JCI154941

Figure 1. The potential utility of ctDNA across the spectrum of human cancers.

Figure 1

MRD, minimum residual disease. Adapted with permission from Cancers (108).